DelveInsight’s, “Intrahepatic Cholangiocarcinoma Pipeline Insight, 2022,” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in the Intrahepatic Cholangiocarcinoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key takeaways from the Intrahepatic Cholangiocarcinoma Pipeline Insight Report
Recent Developmental Activities in the Intrahepatic Cholangiocarcinoma Pipeline
Request a sample and discover the recent breakthroughs happening Intrahepatic Cholangiocarcinoma pipeline landscape @ Intrahepatic Cholangiocarcinoma Pipeline Outlook
Intrahepatic Cholangiocarcinoma Overview
Intrahepatic Cholangiocarcinoma is a cancer that develops in the cells within the bile ducts; both inside and outside the liver. The terms cholangiocarinoma and bile duct cancer are often used to refer to the same condition. This condition occurs slightly more often in males than females and usually affects people who are between 50-70 years old. Signs and symptoms of intrahepatic cholangiocarcinoma include jaundice, abdominal pain, fever, weight loss, weakness and itching. Treatment options may include surgery to remove the bile duct and parts of the liver, chemotherapy and radiation.
Intrahepatic Cholangiocarcinoma Emerging Drugs
Derazantinib: Basilea Pharmaceutica
Derazantinib is an orally administered small molecule inhibitor of the fibroblast growth factor receptor (FGFR) family of kinases. Derazantinib is currently in a registrational phase 2 study inIntrahepatic cholangiocarcinoma (iCCA). In January 2019, Basilea reported results from an interim analysis from this study. The efficacy results were encouraging and the analysis also confirmed the safety profile and tolerability of derazantinib observed in previous clinical studies.
Durvalumab: AstraZeneca
Durvalumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody and a novel immune-checkpoint inhibitor for cancer treatment. Produced by recombinant DNA technology in Chinese Hamster Ovary (CHO) cell suspension culture, durvalumab is a programmed death-ligand 1 (PD-L1) blocking antibody that works to promote normal immune responses that attack tumour cells.
Intrahepatic Cholangiocarcinoma Pipeline Therapeutics Analysis
There are approx. 20+ key companies which are developing the therapies for Intrahepatic Cholangiocarcinoma. The companies which have their Intrahepatic Cholangiocarcinoma drug candidates in the most advanced stage, i.e. phase II include, Basilea Pharmaceutica.
There are many factors affecting the Intrahepatic Cholangiocarcinoma prognosis. Find out these @ Intrahepatic Cholangiocarcinoma Treatment Landscape
Intrahepatic Cholangiocarcinoma Pipeline Therapeutics Assessment
The Intrahepatic Cholangiocarcinoma Pipeline report proffers an integral view of the Intrahepatic Cholangiocarcinoma emerging novel therapies segmented by Stage, Product Type, Molecule Type, Mechanism of Action, and Route of Administration.
Intrahepatic Cholangiocarcinoma Pipeline Report Assessment
Learn more about the novel and emerging Intrahepatic Cholangiocarcinoma pipeline therapies @ Intrahepatic Cholangiocarcinoma Clinical Trials
Scope of the Intrahepatic Cholangiocarcinoma Pipeline Report
Table of Content
Key Questions
Current Treatment Scenario and Emerging Therapies:
For further information on the Intrahepatic Cholangiocarcinoma pipeline therapeutics, reach out to Intrahepatic Cholangiocarcinoma Emerging Therapy
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/